135.07MMarket Cap-999P/E (TTM)
1.530High1.490Low37.35KVolume1.490Open1.490Pre Close56.36KTurnover0.07%Turnover RatioLossP/E (Static)90.08MShares1.92052wk High2.12P/B78.21MFloat Cap0.94552wk Low--Dividend TTM52.16MShs Float28.990Historical High--Div YieldTTM2.69%Amplitude0.945Historical Low1.509Avg Price1Lot Size
Immunic Stock Forum
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients With Post Covid Syndrome
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
PR Newswire· 1 min ago
get the lead out 😜
No comment yet